| Name | Title | Contact Details |
|---|
As part of the state`s premier academic medical center, University of Missouri Health Care offers a full spectrum of care, ranging from primary care to highly specialized, multidisciplinary treatment for patients with the most severe illnesses and injuries. Patients from each of Missouri`s 114 counties are served by approximately 6,000 physicians, nurses and health care professionals at MU Health Care. MU Health Care is a part of University of Missouri Health System, which also includes the MU School of Health Professions, the MU School of Medicine, the MU Sinclair School of Nursing and University Physicians practice plan. University Hospital includes: The Frank L. Mitchell Jr., MD Trauma Center. A nationally accredited Cycle II Chest Pain Center and a nationally accredited Primary Stroke Center, the George D. Peak Memorial Burn and Wound Center. University of Missouri Women`s and Children`s Hospital is Missouri`s only hospital dedicated to women and children. It is the largest pediatric health care facility in mid-Missouri. Ellis Fischel Cancer Center is Missouri`s only hospital dedicated solely to cancer care. Missouri Orthopaedic Institute is the newest and largest freestanding orthopaedic center in mid-Missouri. The Missouri Psychiatric Center offers short-term, intensive inpatient treatment services for adults, adolescents and children at our facility adjacent to University Hospital.
Stinger Medical is a Murfreesboro, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rush-Copley Medical Center, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Aurora, IL. To find more information about Rush-Copley Medical Center, Inc, please visit www.rushcopley.com
Access Lifts and Ramps is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.